SAB BIOTHERAPEUTICS, INC. (SABS) Operating income 2020–2025
SAB BIOTHERAPEUTICS, INC. (SABS) annual operating income history from SEC filings — each fiscal year as reported.
-$49.0MFY2025 · since FY2020: $20.6M → -$49.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$49.0M | -14.1% |
| FY2024 | -$42.9M | -12.7% |
| FY2023 | -$38.1M | -31.7% |
| FY2022 | -$28.9M | -115.9% |
| FY2021 | -$13.4M | -165.2% |
| FY2020 | $20.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More SABS financial trends
SABS RevenueSABS Net incomeSABS Net marginSABS Gross profitSABS Gross marginSABS Operating marginSABS Operating cash flowSABS Free cash flowSABS Capital expendituresSABS Return on equitySABS Stock buybacksSABS Dividends paidSABS Total assetsSABS Total liabilitiesSABS Shareholders’ equitySABS overview →